Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT05729711
Active, not recruiting Observational

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

NCT05729711 · tracked via the Priya Life Science Japan tracker
Sponsor
AstraZeneca
Phase
Observational
Started
2023-04-04
Last updated
2026-09-29

Condition(s) studied

Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

Study summary

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire.

1. Development of related AEs
2. Contributing factors possibly having an impact on the safety and effectiveness
3. Development of unexpected related AEs

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The evaluable patients are those treated with Tezspire for the first time due to "Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy) Exclusion Criteria: None

Primary outcome measure(s)

  • Incidence of ADRs — 156 weeks
    the incidence of ADRs related to Tezspire Safety Specifications: Serious hypersensitivity, infection, malignancy, cardiac disorders

Trial sites (33)

FacilityCityRegionStatus
Research Site Aichi Japan
Research Site Akita Japan
Research Site Aomori Japan
Research Site Chiba Japan
Research Site Fukui Japan
Research Site Fukuoka Japan
Research Site Gifu Japan
Research Site Gunma Japan
Research Site Hiroshima Japan
Research Site Hokkaido Japan
Research Site Hyōgo Japan
Research Site Ibaraki Japan
Research Site Ishikawa Japan
Research Site Kagawa Japan
Research Site Kanagawa Japan
Research Site Kumamoto Japan
Research Site Kyoto Japan
Research Site Mie Japan
Research Site Miyagi Japan
Research Site Nara Japan
Research Site Numakunai Japan
Research Site Okayama Japan
Research Site Osaka Japan
Research Site Ōita Japan
Research Site Saitama Japan
Research Site Shimane Japan
Research Site Shizuoka Japan
Research Site Tochigi Japan
Research Site Tokyo Japan
Research Site Wakayama Japan
Research Site Yamagata Japan
Research Site Yamaguchi Japan
Research Site Yamanashi Japan

More AstraZeneca trials in Japan

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) Active, not recruiting
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Recruiting
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC Active, not recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia Recruiting
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05729711 on ClinicalTrials.gov ↗ ← All trials in Japan